-
Capital, M&A & Industry Strategy2 weeks ago
Biomarin nabs big royalties in achondroplasia patent settlement with Ascendis
Biomarin has granted Ascendis a non-exclusive, worldwide license to use navepegritide, the active ingredient in the latter company’s recently approved achondroplasia drug Yuviwel, in exchange for...
-
Uncategorized2 weeks ago
Arrowhead’s new Redemplo findings in severe hypertriglyceridemia have analysts split
Safety and dosing are likely to be “key differentiators” for Arrowhead Pharmaceuticals as it looks to challenge Ionis Pharmaceuticals’ lead in the severe hypertriglyceridemia market.
-
Uncategorized2 weeks ago
Deal-hungry Lilly strikes up to $2.9B immuno play for Merida
With the acquisition of Merida Biosciences, Eli Lilly is gaining a precision degradation platform for therapies that selectively target and destroy pathologic antibodies for allergic and...
-
Uncategorized2 weeks agoFour scientists awarded $3m for tau-driven disease research
A group of charities have announced $3 million in grants to fund four innovative research projects over two years, stemming from the 2026 Tauopathy Challenge Workshop. ...
-
Uncategorized2 weeks ago
BMS’ neuro renaissance was built on back of Celgene mega-merger
Well-known for its oncology efforts and making recent headlines for a rumored mega merger with AstraZeneca, Bristol Myers Squibb is also dedicating considerable resources to neurological...
-
Uncategorized2 weeks ago
China poses increasing security risk as US biotech innovation edge erodes
The U.S. is scrambling to compete with a strategically positioned China on the biotech stage as the Asian country surpasses America in biomedical research and clinical...
-
Uncategorized2 weeks agoStockWatch: Revolution Shares Stay Flat Despite Historic FDA Approval of Oral Pancreatic Cancer Therapy
Revolution Medicines (Nasdaq: RVMD) appeared to have the makings of another strong stock surge this past week when the FDA approved the company’s historic oral therapy...
-
Uncategorized3 weeks ago
Navigating regulatory fragmentation in the convergence of synthetic biology, artificial intelligence, and automation
Post Content
-
AI, Machine Learning & Computational Biology3 weeks agoJuul gets OK to sell updated vaping device with age-gating technology
Juul gets OK to sell updated vaping device with age-gating technology
-
AI, Machine Learning & Computational Biology3 weeks agoOpinion: The unintended consequences of the Lindsay Clancy case
Opinion: The unintended consequences of the Lindsay Clancy case
Ensuring safety and accountability in China’s biomedical translation system
Blood centers can help biopharma scale cell and gene therapies
Psychedelics at FDA, Mike Davis’ CDER and translating tRNAs — a BioCentury podcast
Scientists turn pig semen extract into eye drops that kill cancer in mice
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
